Validation of the new classification of pauci-immune glomerulonephritis in a United States cohort and its correlation with renal outcome

BMC Nephrology

Volumn 14, Issue 1, 2013, Pages

  Ellis, Carla L ^a,c   Manno, Rebecca L ^a   Havill, John P ^a   Racusen, Lorraine C ^a   Geetha, Duvuru ^a,b  

^a JOHNS HOPKINS HOSPITAL   (United States)

^b JOHNS HOPKINS BAYVIEW MEDICAL CENTER   (United States)

^c EMORY UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

ANCA vasculitis; Histologic classification; Pauci immune glomerulonephritis; Renal outcome

Indexed keywords

CORTICOSTEROID; CYCLOPHOSPHAMIDE; CYCLOSPORIN; IMMUNOGLOBULIN; METHOTREXATE; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; RITUXIMAB; STEROID;

ADULT; ARTICLE; CALCULATION; COHORT ANALYSIS; CONTROLLED STUDY; DISEASE ASSOCIATION; DISEASE CLASSIFICATION; FEMALE; GLOMERULUS FILTRATION RATE; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; IMMUNE COMPLEX NEPHRITIS; IMMUNOSUPPRESSIVE TREATMENT; KIDNEY BIOPSY; KIDNEY FAILURE; KIDNEY FUNCTION; KIDNEY GRAFT; MAJOR CLINICAL STUDY; MALE; MEDICAL RECORD; OUTCOME ASSESSMENT; PREDICTIVE VALUE; RENAL REPLACEMENT THERAPY; RETROSPECTIVE STUDY; SURVIVAL; UNITED STATES; VALIDATION PROCESS; VASCULITIS;

AUTOIMMUNE DISEASES; BIOPSY; COHORT STUDIES; FEMALE; GLOMERULAR FILTRATION RATE; GLOMERULOSCLEROSIS, FOCAL SEGMENTAL; HUMANS; MALE; MIDDLE AGED; REPRODUCIBILITY OF RESULTS; SENSITIVITY AND SPECIFICITY; STATISTICS AS TOPIC; TERMINOLOGY AS TOPIC; UNITED STATES;

EID: 84884964217     PISSN: None     EISSN: 14712369     Source Type: Journal    
DOI: 10.1186/1471-2369-14-210     Document Type: Article

References (30)

1. Outcome of ANCA-associated renal vasculitis: a 5-year retrospective study. Booth AD, Almond MK, Burns A, Ellis P, Gaskin G, Neild GH, Plaisance M, Pusey CD, Jayne DR, Am J Kidney Dis 2003 41 4 776 784 10.1016/S0272-6386(03) 00025-8 12666064
2. ANCA glomerulonephritis and vasculitis: a Chapel Hill perspective. Falk RJ, Nachman PH, Hogan SL, Jennette JC, Semin Nephrol 2000 20 3 233 243 10855933
3. Pauci-immune renal vasculitis: natural history, prognostic factors, and impact of therapy. Cohen BA, Clark WF, Am J Kidney Dis 2000 36 5 914 924 10.1053/ajkd.2000.19082 11054347
4. Small-vessel vasculitis. Jennette JC, Falk RJ, N Engl J Med 1997 337 21 1512 1523 10.1056/NEJM199711203372106 9366584
5. Crescentic glomerulonephritis with a paucity of glomerular immunoglobulin localization. Harris AA, Falk RJ, Jennette JC, Am J Kidney Dis 1998 32 1 179 184 9669443
6. A randomized trial of maintenance therapy for vasculitis associated with antineutrophil cytoplasmic autoantibodies. Jayne D, Rasmussen N, Andrassy K, Bacon P, Tervaert JW, Dadoniene J, Ekstrand A, Gaskin G, Gregorini G, De Groot K, et al. N Engl J Med 2003 349 1 36 44 10.1056/NEJMoa020286 12840090
7. Randomized trial of plasma exchange or high-dosage methylprednisolone as adjunctive therapy for severe renal vasculitis. Jayne DR, Gaskin G, Rasmussen N, Abramowicz D, Ferrario F, Guillevin L, Mirapeix E, Savage CO, Sinico RA, Stegeman CA, et al. J Am Soc Nephrol 2007 18 7 2180 2188 10.1681/ASN.2007010090 17582159
8. Predictors of relapse and treatment resistance in antineutrophil cytoplasmic antibody-associated small-vessel vasculitis. Hogan SL, Falk RJ, Chin H, Cai J, Jennette CE, Jennette JC, Nachman PH, Ann Intern Med 2005 143 9 621 631 10.7326/0003-4819-143-9-200511010-00005 16263884
9. Renal survival and prognostic factors in patients with PR3-ANCA associated vasculitis with renal involvement. Slot MC, Tervaert JW, Franssen CF, Stegeman CA, Kidney Int 2003 63 2 670 677 10.1046/j.1523-1755.2003.00769.x 12631133
10. Renal histopathology and clinical course in 94 patients with Wegener's granulomatosis. Aasarod K, Bostad L, Hammerstrom J, Jorstad S, Iversen BM, Nephrol Dial Transplant 2001 16 5 953 960 10.1093/ndt/16.5.953 11328900
11. Kidney biopsy as a predictor for renal outcome in ANCA-associated necrotizing glomerulonephritis. Bajema IM, Hagen EC, Hermans J, Noel LH, Waldherr R, Ferrario F, Van Der Woude FJ, Bruijn JA, Kidney Int 1999 56 5 1751 1758 10.1046/j.1523-1755.1999.00758.x 10571783
12. Clinical and histologic determinants of renal outcome in ANCA-associated vasculitis: A prospective analysis of 100 patients with severe renal involvement. de Lind van Wijngaarden RA, Hauer HA, Wolterbeek R, Jayne DR, Gaskin G, Rasmussen N, Noel LH, Ferrario F, Waldherr R, Hagen EC, J Am Soc Nephrol 2006 17 8 2264 2274 10.1681/ASN.2005080870 16825335
13. Long-term renal injury in ANCA-associated vasculitis: an analysis of 31 patients with follow-up biopsies. Hauer HA, Bajema IM, Hagen EC, Noel LH, Ferrario F, Waldherr R, Van Houwelingen HC, Lesavre P, Sinico RA, van der Woude F, et al. Nephrol Dial Transplant 2002 17 4 587 596 10.1093/ndt/17.4.587 11917050
14. Determinants of outcome in ANCA-associated glomerulonephritis: a prospective clinico-histopathological analysis of 96 patients. Hauer HA, Bajema IM, Van Houwelingen HC, Ferrario F, Noel LH, Waldherr R, Jayne DR, Rasmussen N, Bruijn JA, Hagen EC, Kidney Int 2002 62 5 1732 1742 10.1046/j.1523-1755.2002. 00605.x 12371974
15. Histological and clinical predictors of early and late renal outcome in ANCA-associated vasculitis. Neumann I, Kain R, Regele H, Soleiman A, Kandutsch S, Meisl FT, Nephrol Dial Transplant 2005 20 1 96 104 10.1093/ndt/gfh563 15546891
16. An index for renal outcome in ANCA-associated glomerulonephritis. Vergunst CE, Van Gurp E, Hagen EC, Van Houwelingen HC, Hauer HA, Noel LH, Waldherr R, Ferrario F, van der Woude FJ, Bruijn JA, et al. Am J Kidney Dis 2003 41 3 532 538 10.1053/ajkd.2003.50115 12612975
17. Correlation of percentage of normal glomeruli with renal outcome in Wegener's granulomatosis. Haroun MK, Stone JH, Nair R, Racusen L, Hellmann DB, Eustace JA, Am J Nephrol 2002 22 5-6 497 503 12381950
18. Clinicopathologic predictors of death and ESRD in patients with pauci-immune necrotizing glomerulonephritis. Kapitsinou PP, Ioannidis JP, Boletis JN, Sotsiou F, Nakopoulou L, Daphnis E, Moutsopoulos HM, Am J Kidney Dis 2003 41 1 29 37 10.1053/ajkd.2003.50013 12500219
19. Histopathologic classification of ANCA-associated glomerulonephritis. Berden AE, Ferrario F, Hagen EC, Jayne DR, Jennette JC, Joh K, Neumann I, Noel LH, Pusey CD, Waldherr R, J Am Soc Nephrol 2010 21 10 1628 1636 10.1681/ASN.2010050477 20616173
20. Nomenclature of systemic vasculitides. Proposal of an international consensus conference. Jennette JC, Falk RJ, Andrassy K, Bacon PA, Churg J, Gross WL, Hagen EC, Hoffman GS, Hunder GG, Kallenberg CG, et al. Arthritis Rheum 1994 37 2 187 192 10.1002/art.1780370206 8129773
21. A more accurate method to estimate glomerular filtration rate from serum creatinine: a new prediction equation. Modification of Diet in Renal Disease Study Group. Levey AS, Bosch JP, Lewis JB, Greene T, Rogers N, Roth D, Ann Intern Med 1999 130 6 461 470 10.7326/0003-4819-130-6-199903160-00002 10075613
22. Re-evaluation of the histopathologic classification of ANCA-associated glomerulonephritis: a study of 121 patients in a single center. Chang DY, Wu LH, Liu G, Chen M, Kallenberg CG, Zhao MH, Nephrol Dial Transplant 2012 27 6 2343 2349 10.1093/ndt/gfr643 22121235
23. Tubular lesions predict renal outcome in antineutrophil cytoplasmic antibody-associated glomerulonephritis after rituximab therapy. Berden AE, Jones RB, Erasmus DD, Walsh M, Noel LH, Ferrario F, Waldherr R, Bruijn JA, Jayne DR, Bajema IM, J Am Soc Nephrol 2012 23 2 313 321 10.1681/ASN.2011040330 22095945
24. Differences between anti-myeloperoxidase- and anti-proteinase 3-associated renal disease. Franssen CF, Gans RO, Arends B, Hageluken C, Ter Wee PM, Gerlag PG, Hoorntje SJ, Kidney Int 1995 47 1 193 199 10.1038/ki.1995.23 7731146
25. Renal histology in ANCA-associated vasculitis: differences between diagnostic and serologic subgroups. Hauer HA, Bajema IM, Van Houwelingen HC, Ferrario F, Noel LH, Waldherr R, Jayne DR, Rasmussen N, Bruijn JA, Hagen EC, Kidney Int 2002 61 1 80 89 10.1046/j.1523-1755.2002.00089.x 11786087
26. Treatment response and relapse in antineutrophil cytoplasmic autoantibody-associated microscopic polyangiitis and glomerulonephritis. Nachman PH, Hogan SL, Jennette JC, Falk RJ, J Am Soc Nephrol 1996 7 1 33 39 8808107
27. Rituximab versus cyclophosphamide in ANCA-associated renal vasculitis. Jones RB, Tervaert JW, Hauser T, Luqmani R, Morgan MD, Peh CA, Savage CO, Segelmark M, Tesar V, Van Paassen P, N Engl J Med 2010 363 3 211 220 10.1056/NEJMoa0909169 20647198
28. ANCA-associated vasculitis with renal involvement: an outcome analysis. Weidner S, Geuss S, Hafezi-Rachti S, Wonka A, Rupprecht HD, Nephrol Dial Transplant 2004 19 6 1403 1411 10.1093/ndt/gfh161 15069175
29. Improved outcome in anti-neutrophil cytoplasmic antibody (ANCA)-associated glomerulonephritis: a 30-year follow-up study. Hilhorst M, Wilde B, Van Paassen P, Winkens B, Van Breda Vriesman P, Cohen Tervaert JW, Nephrol Dial Transplant 2013 28 2 373 379 Feb. doi: 10.1093 10.1093/ndt/gfs428 23223225
30. Estimating Renal Survival Using the ANCA-Associated GN Classification. Hilhorst M, Wilde B, Van Breda VP, Van Paassen P, Cohen Tervaert JW, J Am Soc Nephrol 2013 24 9 1371 1375 10.1681/ASN.2012090912 23766532